Theravance Biopharma, Inc. (TBPH)
Valuation Overview•Is Theravance Biopharma, Inc. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
High-quality fundamentals with a strong composite quality score of 75/100, backed by robust profitability and solvency.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Verdict: Solid fundamental quality, though profitability presents a headwind.
Wall Street is cautious, forecasting potential downside with steady expected earnings growth. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
TBPH demonstrates strong business quality with robust profitability and healthy margins. This is backed by a fortress balance sheet, holding significant net cash ($92M) and minimal debt risk.
The company is driving exceptional top-line expansion (27.9% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (0.1%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $17.7M | +66.9% | +27.9% | +8.4% | +9.8% | |
| EBITDA | -$6.9M | — | +55.7% | — | — | |
| Net Income | -$4.9M | +287.7% | -50.5% | — | — | |
| EPS (Diluted) | $-0.10 | +279.1% | — | — | — | |
| Free Cash Flow | $73.3M | +2109.8% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 80.4% | 74.7% | -9.9% | 40.4% |
| Operating Margin | 0.1% | -60.9% | -165.6% | -404.2% |
| Net Margin | 104.3% | -28.4% | 250.6% | -206.0% |
| FCF Margin | 244.8% | 50.7% | -119.0% | -301.1% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.03 | $-0.10 | -443.6% | ||
| Q1'26 | $0.44 | $0.06 | -86.4% | ||
| Q4'25 | $-0.03 | $0.04 | +233.3% | ||
| Q3'25 | $-0.14 | $-0.08 | +42.9% | ||
| Q2'25 | $-0.11 | $-0.17 | -54.5% | ||
| Q1'25 | $-0.05 | $-0.05 | +0.0% | ||
| Q4'24 | $-0.10 | $-0.06 | +40.0% | ||
| Q3'24 | $-0.09 | $-0.13 | -44.4% |
Total return is +56.1% (1Y), outperforming the benchmark by +31.1%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -8.7% | -18.0% | — |
| 1Y | +56.1% | +31.1% | — |
| 3YCAGR | +16.4% | -2.8% | — |
| 5YCAGR | -1.1% | -13.5% | — |
| 10YCAGR | -3.2% | -16.3% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Theravance Biopharma, Inc. (TBPH) valuation, health, and returns.
Based on peer relative multiples, Theravance Biopharma, Inc. appears Slightly cheap versus peers compared to industry peers.
Theravance Biopharma, Inc. has multiple valuation anchors: Peer Relative Fair Value: $19.43 | Wall Street Analyst Target: $14.00 (implying -15.6% upside). A convergence of these signals offers higher conviction.
Theravance Biopharma, Inc. displays good financial health with a composite quality score of 75/100, supported by a Altman Z-Score of 0.9 (distress zone), Piotroski F-Score of 6/9, Return on Invested Capital (ROIC) of -5.1%.
Theravance Biopharma, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Theravance Biopharma, Inc.'s current growth trajectory is Accelerating. The company achieved +66.9% 1Y revenue growth and +279.1% 1Y EPS growth, compared to its 3Y revenue CAGR of +27.9%.
Wall Street consensus is Hold based on 16 analysts, beating EPS expectations in 50% of recent quarters with a -2-quarter streak. The consensus price target represents a -15.6% change from current levels.
Investment risks for Theravance Biopharma, Inc. include: -34.6% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.78x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.